Parham Academy LLC
European Academy of Biomedical Sciences


Our news & hot issues


ISI Impact factor= 5.49 (Q1)



Each weekend, you are linked to the best article that , during each week, I have read and found it great in the field of Cancer and Pharmacology. I try to encourage the fellow researchers and post-graduate students to read so much as they can about new therapeutics.
-------------------------------------------

Weekend Recipe for January 2016 - the first week

Antibody Drug Conjugates for Cancer Therapy

Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.

Download this recipe

To download other weekend recipes click here.




Author watson Home 13:34:12 | | | printer friendly | | create pdf of this news item


Our article: Therapeutic miRNAs


 Pharmacological Research




Headlines





Date published: not known
Details

»Investigating flu vaccine effectiveness
»How lipopolysaccharides bridge the gap
»SNF'ing out antitumor immunity
»CRISPR-Cas accelerates phage evolution
»Recognizing danger signals
»It's a wrap
»Forming photonic bound states
»A way to prevent generalized seizures?
»Air pollution evolution
»Left- or right-handed C-H bond activation


Date published: not known
Details

»G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? [Minireview-Axelrod Symposium 2017]
Estimates vary regarding the number of G protein-coupled receptors (GPCRs), the largest family of m ...
»Biased Agonism in Drug Discovery--Is It Too Soon to Choose a Path? [Minireview-Axelrod Symposium 2017]
A single receptor can activate multiple signaling pathways that have distinct or even opposite effe ...
»Is the Quest for Signaling Bias Worth the Effort? [Perspective-Axelrod Symposium 2017]
The question of whether signaling bias is a viable discovery strategy for drug therapy is discussed ...
»cAMP Signaling Compartmentation: Adenylyl Cyclases as Anchors of Dynamic Signaling Complexes [Minireview-Axelrod Symposium 2017]
It is widely accepted that cAMP signaling is compartmentalized within cells. However, our knowledge ...
»Caveolins as Regulators of Stress Adaptation [Minireview-Axelrod Symposium 2017]
Caveolins have been recognized over the past few decades as key regulators of cell physiology. They ...


Date published: not known
Details

»Exploiting the geometry of the solution space to reduce sensitivity to neuromotor noise
»The self-organization of plant microtubules inside the cell volume yields their cortical localization, stable alignment, and sensitivity to external cues
»Prediction of infectious disease epidemics via weighted density ensembles
»Control fast or control smart: When should invading pathogens be controlled?
»Metabolic enzyme cost explains variable trade-offs between microbial growth rate and yield
»Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
»In silico analysis of antibiotic-induced Clostridium difficile infection: Remediation techniques and biological adaptations
»A stochastic and dynamical view of pluripotency in mouse embryonic stem cells
»Integrating linear optimization with structural modeling to increase HIV neutralization breadth
»A multiscale modelling approach to assess the impact of metabolic zonation and microperfusion on the hepatic carbohydrate metabolism
»Optimizing homeostatic cell renewal in hierarchical tissues
»A comprehensive and quantitative comparison of text-mining in 15 million full-text articles versus their corresponding abstracts


Date published: not known
Details


THE FOUNDER and CEO

Parham Jabbarzadeh Kaboli, PhD

Research scientist
in molecular medicine


Expert in:

Cell and molecular Biology
Modelling and drug discovery
Cancer signaling pathways

H-index= 3 (Google Scholar)
i10-index= 3
Overall ISI impact factor= 18.15
Overall citation= 110 (Google Scholar)

Memberships:

The American Society for Pharmacology and Experimental Therapeutics (ASPET)

American Association for Cancer Research (AACR)

European Association for Cancer Research (EACR)

American Association for Advancement of Science (AAAS)



CONTACT INFORMATION


Affiliation:
Department of Biomedical Science,
Faculty of Medicine and Health Sciences,
Universiti Putra Malaysia,
UPM Serdang 43400,
Selangor, Malaysia

E-Mail: parham@gromacs.net
Telegram: telegram.me/parhamacademy
Featured Publication





View the full list.
Archives

Welcome

Username:

Password:



[ ]







This site is powered by Parham Academy.
This site is powered by Parham Academy.
Render time: 0.3790 sec, 0.1281 of that for queries.